CALT News and Press, Calliditas Therapeutics AB From 01/28/21

Calliditas announces termination of the proposed global offering PR Newswire STOCKHOLM , Jan. 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; Nasdaq - CALT) today announced that despite significant interest, it wil...

Calliditas Therapeutics ([[CALT]] -10.3%) launched a proposed public offering of American Depositary Shares (representing two common shares), in the U.S. for trading on Nasdaq Global Select Market and a concurrent private placement of common shares (global offering).Size of the glob...

Calliditas Therapeutics launches proposed global offering PR Newswire STOCKHOLM , Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depo...

Calliditas Therapeutics ([[CALT]]) has announced that all 360 patients have been enrolled for the global Phase 3 trial NefIgArd comprising Part A and Part B, evaluating the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN).Calliditas read out topline data from P...

Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial PR Newswire STOCKHOLM , Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enro...

Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day...

Calliditas Therapeutics' ([[CALT]] +6.4%) subsidiary Genkyotex has announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset.The study in 46 healthy volunteers demonstrated that setanaxib is well tolerated ...

Positive Phase 1 results in high-dose setanaxib trial PR Newswire STOCKHOLM , Jan. 18, 2021 /PRNewswire/ -- Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT), today announced positive Phase 1 data...

Agenda for Calliditas virtual R&D Day on January 20, 2021 Agenda for Calliditas virtual R&D Day on January 20, 2021 PR Newswire STOCKHOLM , Jan. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ...

Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex STOCKHOLM , Dec. 16, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) submitted a simplified public mandatory offe...